Idelalisib

(Zydelig)

Idelalisib

Drug updated on 11/13/2023

Dosage FormTablet (oral; 100 mg, 150 mg)
Drug ClassKinase Inhibitors
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of patients with relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities.

Product Monograph / Prescribing Information

Document TitleYearSource
Zydelig (idelalisib) Prescribing Information.2022Gilead Sciences, Inc., Foster City, CA

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines